ID   T24
AC   CVCL_0554
SY   T-24; T 24
DR   BTO; BTO:0001345
DR   CLO; CLO_0009235
DR   CLO; CLO_0009245
DR   CLO; CLO_0050843
DR   CLO; CLO_0050844
DR   EFO; EFO_0002864
DR   MCCL; MCC:0000455
DR   CLDB; cl4452
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BCRC; 60062
DR   BCRJ; 0231
DR   BioSample; SAMN03472744
DR   BioSample; SAMN03473324
DR   BioSample; SAMN10987918
DR   CCRID; 1101HUM-PUMC000295
DR   CCRID; 4201HUM-CCTCC00078
DR   CCRID; 5301HUM-KCB92027YJ
DR   Cell_Model_Passport; SIDM01184
DR   ChEMBL-Cells; CHEMBL3307700
DR   ChEMBL-Targets; CHEMBL614774
DR   CLS; 300352/p619_T24
DR   Cosmic; 716174
DR   Cosmic; 724812
DR   Cosmic; 755400
DR   Cosmic; 845561
DR   Cosmic; 846275
DR   Cosmic; 925832
DR   Cosmic; 928817
DR   Cosmic; 943742
DR   Cosmic; 1001664
DR   Cosmic; 1016880
DR   Cosmic; 1046673
DR   Cosmic; 1285130
DR   Cosmic; 1285985
DR   Cosmic; 1302355
DR   Cosmic; 1927302
DR   Cosmic; 1938698
DR   Cosmic; 2037960
DR   Cosmic; 2050465
DR   Cosmic; 2057459
DR   Cosmic; 2444230
DR   Cosmic; 2686118
DR   Cosmic; 2700999
DR   Cosmic-CLP; 724812
DR   DepMap; ACH-000018
DR   DSMZ; ACC-376
DR   GDSC; 724812
DR   GEO; GSM136233
DR   GEO; GSM492493
DR   GEO; GSM887683
DR   GEO; GSM888775
DR   GEO; GSM1374940
DR   GEO; GSM1574571
DR   GEO; GSM1670520
DR   IARC_TP53; 3722
DR   IARC_TP53; 21131
DR   IARC_TP53; 30178
DR   KCB; KCB 92027YJ
DR   KCLB; 30004
DR   LiGeA; CCLE_255
DR   LINCS_HMS; 50048
DR   Lonza; 862
DR   PharmacoDB; T24_1554_2019
DR   PRIDE; PXD003105
DR   Progenetix; CVCL_0554
DR   RCB; RCB0431
DR   RCB; RCB2536
DR   TKG; TKG 0443
DR   TOKU-E; 3252
DR   Wikidata; Q54971454
RX   CelloPub=CLPUB00543;
RX   DOI=10.11418/jtca1981.18.4_329;
RX   PubMed=571047;
RX   PubMed=651066;
RX   PubMed=663932;
RX   PubMed=833871;
RX   PubMed=864752;
RX   PubMed=870558;
RX   PubMed=2607719;
RX   PubMed=3518877;
RX   PubMed=3708594;
RX   PubMed=4133950;
RX   PubMed=6220172;
RX   PubMed=6244232;
RX   PubMed=6823318;
RX   PubMed=6826254;
RX   PubMed=7017212;
RX   PubMed=7185004;
RX   PubMed=7787250;
RX   PubMed=8873383;
RX   PubMed=9247707;
RX   PubMed=9290701;
RX   PubMed=9850064;
RX   PubMed=11921286;
RX   PubMed=12068308;
RX   PubMed=15846775;
RX   PubMed=16885334;
RX   PubMed=19105184;
RX   PubMed=19375735;
RX   PubMed=22460905;
RX   PubMed=23401075;
RX   PubMed=24018021;
RX   PubMed=24035680;
RX   PubMed=24367658;
RX   PubMed=24376083;
RX   PubMed=24459064;
RX   PubMed=25997541;
RX   PubMed=26055179;
RX   PubMed=26972028;
RX   PubMed=27141528;
RX   PubMed=27270441;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=29732388;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31978347;
CC   Part of: BLA-40 bladder carcinoma cell line panel.
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: UBC-40 urothelial bladder cancer cell line index.
CC   Population: Caucasian; Swedish.
CC   Doubling time: 19 hours (PubMed=4133950); 21 hours (PubMed=3708594); 23.2 hours (PubMed=26055179); ~48 hours (DSMZ); ~1 day (lot 02052018) (JCRB).
CC   HLA typing: A*01,03; B*18,w35; C*w04 (ATCC).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (PubMed=12068308; ATCC).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680; PubMed=31068700).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (PubMed=7787250; ATCC).
CC   Omics: Array-based CGH.
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Exosome proteome analysis.
CC   Omics: GPI-anchored proteins analysis by proteomics.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Proteome analysis by 2D-DE/MS.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=1.35%; Native American=0.28%; East Asian, North=4.67%; East Asian, South=0%; South Asian=0%; European, North=65.79%; European, South=27.92% (PubMed=30894373).
CC   Derived from sampling site: Urinary bladder.
ST   Source(s): ATCC; CCRID; CLS; Cosmic-CLP; DSMZ; JCRB; KCLB; PubMed=11416159; PubMed=27270441; RCB; TKG
ST   Amelogenin: X
ST   CSF1PO: 10,12 (ATCC; CCRID; CLS; Cosmic-CLP; DSMZ; JCRB; KCLB; PubMed=27270441; TKG)
ST   CSF1PO: 12 (RCB)
ST   D12S391: 17,18
ST   D13S317: 9,12 (DSMZ)
ST   D13S317: 12 (ATCC; CCRID; CLS; Cosmic-CLP; JCRB; KCLB; PubMed=27270441; RCB; TKG)
ST   D16S539: 9
ST   D1S1656: 12,15
ST   D18S51: 16,18
ST   D19S433: 13,14
ST   D21S11: 29
ST   D2S1338: 20,23
ST   D3S1358: 16 (CCRID; KCLB)
ST   D3S1358: 16,21 (CLS)
ST   D5S818: 10 (RCB)
ST   D5S818: 10,12 (ATCC; CCRID; CLS; Cosmic-CLP; DSMZ; JCRB; KCLB; PubMed=27270441; TKG)
ST   D6S1043: 11
ST   D7S820: 10,11
ST   D8S1179: 9,14 (CLS)
ST   D8S1179: 14 (CCRID; PubMed=11416159)
ST   FGA: 17,22
ST   Penta D: 11,15
ST   Penta E: 7,10
ST   TH01: 6
ST   TPOX: 8,11
ST   vWA: 17 (ATCC; CCRID; Cosmic-CLP; JCRB; RCB; TKG)
ST   vWA: 17,19 (CLS; DSMZ; KCLB; PubMed=11416159; PubMed=27270441)
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   82Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 23-09-21; Version: 39
RX   CelloPub=CLPUB00543;
RA   Min Q., Cao S.-N., Gan Y.-P., Song T.-S., Liu F.-X., Ning Z.-F.;
RT   "Bladder cancer chemotherapy resistant cell harbors stem-like
RT   characteristics construction and characterization of T24 resistance
RT   strain of bladder cancer.";
RL   Clin. Oncol. J. 1:1004.09-1004.12(2019).
RX   DOI=10.11418/jtca1981.18.4_329;
RA   Tanabe H., Takada Y., Minegishi D., Kurematsu M., Masui T.,
RA   Mizusawa H.;
RT   "Cell line individualization by STR multiplex system in the cell bank
RT   found cross-contamination between ECV304 and EJ-1/T24.";
RL   Tissue Cult. Res. Commun. 18:329-338(1999).
RX   PubMed=571047;
RA   Fogh J.;
RT   "Cultivation, characterization, and identification of human tumor
RT   cells with emphasis on kidney, testis, and bladder tumors.";
RL   Natl. Cancer Inst. Monogr. 49:5-9(1978).
RX   PubMed=651066; DOI=10.5980/jpnjurol1928.69.1_40;
RA   Kato T., Ishikawa K., Nemoto R.;
RT   "Morphologic characterization of two established cell lines, T24 and
RT   MGH-U1, derived from human bladder carcinoma.";
RL   Nihon Hinyokika Gakkai Zasshi 69:40-46(1978).
RX   PubMed=663932; DOI=10.1620/tjem.124.33;
RA   Kato T., Ishikawa K., Nemoto R., Senoo A., Amano Y.;
RT   "Morphological characterization of two established cell lines, T24 and
RT   MGH-U1, derived from human urinary bladder carcinoma.";
RL   Tohoku J. Exp. Med. 124:339-349(1978).
RX   PubMed=833871; DOI=10.1093/jnci/58.2.209;
RA   Fogh J., Wright W.C., Loveless J.D.;
RT   "Absence of HeLa cell contamination in 169 cell lines derived from
RT   human tumors.";
RL   J. Natl. Cancer Inst. 58:209-214(1977).
RX   PubMed=864752; DOI=10.1093/jnci/58.6.1743;
RA   Marshall C.J., Franks L.M., Carbonell A.W.;
RT   "Markers of neoplastic transformation in epithelial cell lines derived
RT   from human carcinomas.";
RL   J. Natl. Cancer Inst. 58:1743-1751(1977).
RX   PubMed=870558; DOI=10.1177/25.4.870558;
RA   Benham F.J., Cottell D.C., Franks L.M., Wilson P.D.;
RT   "Alkaline phosphatase activity in human bladder tumor cell lines.";
RL   J. Histochem. Cytochem. 25:266-274(1977).
RX   PubMed=2607719; DOI=10.5980/jpnjurol1989.80.988;
RA   Kihara K., Kageyama Y., Sumi S., Higashi Y., Fukui I., Oshima H.;
RT   "A study of intercellular communication of human transitional cell
RT   carcinoma cell lines.";
RL   Nihon Hinyokika Gakkai Zasshi 80:988-994(1989).
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
RX   PubMed=3708594;
RA   Masters J.R.W., Hepburn P.J., Walker L., Highman W.J.,
RA   Trejdosiewicz L.K., Povey S., Parkar M., Hill B.T., Riddle P.R.,
RA   Franks L.M.;
RT   "Tissue culture model of transitional cell carcinoma: characterization
RT   of twenty-two human urothelial cell lines.";
RL   Cancer Res. 46:3630-3636(1986).
RX   PubMed=4133950; DOI=10.1002/ijc.2910110327;
RA   Bubenik J., Baresova M., Viklicky V., Jakoubkova J., Sainerova H.,
RA   Donner J.;
RT   "Established cell line of urinary bladder carcinoma (T24) containing
RT   tumour-specific antigen.";
RL   Int. J. Cancer 11:765-773(1973).
RX   PubMed=6220172;
RA   Dracopoli N.C., Fogh J.;
RT   "Polymorphic enzyme analysis of cultured human tumor cell lines.";
RL   J. Natl. Cancer Inst. 70:469-476(1983).
RX   PubMed=6244232;
RA   Williams R.D.;
RT   "Human urologic cancer cell lines.";
RL   Invest. Urol. 17:359-363(1980).
RX   PubMed=6823318; DOI=10.1038/301429a0;
RA   O'Toole C.M., Povey S., Hepburn P.J., Franks L.M.;
RT   "Identity of some human bladder cancer cell lines.";
RL   Nature 301:429-430(1983).
RX   PubMed=6826254; DOI=10.1002/ijc.2910310308;
RA   Paulie S., Hansson Y., Lundblad M.-L., Perlmann P.;
RT   "Lectins as probes for identification of tumor-associated antigens on
RT   urothelial and colonic carcinoma cell lines.";
RL   Int. J. Cancer 31:297-303(1983).
RX   PubMed=7017212; DOI=10.1093/jnci/66.6.1003;
RA   Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.;
RT   "HLA-A, B, C and DR alloantigen expression on forty-six cultured human
RT   tumor cell lines.";
RL   J. Natl. Cancer Inst. 66:1003-1012(1981).
RX   PubMed=7185004; DOI=10.2302/kjm.31.127;
RA   Tachibana M.;
RT   "Studies on cellular adhesiveness in five different culture cell lines
RT   derived from carcinoma of the urinary bladder.";
RL   Keio J. Med. 31:127-148(1982).
RX   PubMed=7787250;
RA   Cooper M.J., Haluschak J.J., Johnson D., Schwartz S., Morrison L.J.,
RA   Lippa M., Hatzivassiliou G., Tan J.;
RT   "p53 mutations in bladder carcinoma cell lines.";
RL   Oncol. Res. 6:569-579(1994).
RX   PubMed=8873383; DOI=10.1007/BF00295899;
RA   Stadler W.M., Olopade O.I.;
RT   "The 9p21 region in bladder cancer cell lines: large homozygous
RT   deletion inactivate the CDKN2, CDKN2B and MTAP genes.";
RL   Urol. Res. 24:239-244(1996).
RX   PubMed=9247707; DOI=10.1080/15216549700202901;
RA   Hatakeyama S., Gao Y.-H., Ohara-Nemoto Y., Kataoka H., Satoh M.;
RT   "Expression of bone morphogenetic proteins of human neoplastic
RT   epithelial cells.";
RL   Biochem. Mol. Biol. Int. 42:497-505(1997).
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
RX   PubMed=9850064;
RA   Markl I.D.C., Jones P.A.;
RT   "Presence and location of TP53 mutation determines pattern of
RT   CDKN2A/ARF pathway inactivation in bladder cancer.";
RL   Cancer Res. 58:5348-5353(1998).
RX   PubMed=11921286; DOI=10.1002/gcc.10050;
RA   Williams S.V., Sibley K.D., Davies A.M., Nishiyama H., Hornigold N.,
RA   Coulter J., Kennedy W.J., Skilleter A., Habuchi T., Knowles M.A.;
RT   "Molecular genetic analysis of chromosome 9 candidate tumor-suppressor
RT   loci in bladder cancer cell lines.";
RL   Genes Chromosomes Cancer 34:86-96(2002).
RX   PubMed=12068308; DOI=10.1038/nature00766;
RA   Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S.,
RA   Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N.,
RA   Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J.,
RA   Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S.,
RA   Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.,
RA   Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J.,
RA   Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A.,
RA   Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T.,
RA   Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R.,
RA   Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.;
RT   "Mutations of the BRAF gene in human cancer.";
RL   Nature 417:949-954(2002).
RX   PubMed=15846775; DOI=10.1002/gcc.20166;
RA   Williams S.V., Adams J., Coulter J., Summersgill B.M., Shipley J.M.,
RA   Knowles M.A.;
RT   "Assessment by M-FISH of karyotypic complexity and cytogenetic
RT   evolution in bladder cancer in vitro.";
RL   Genes Chromosomes Cancer 43:315-328(2005).
RX   PubMed=16885334; DOI=10.1158/0008-5472.CAN-06-1182;
RA   Lopez-Knowles E., Hernandez S., Malats N., Kogevinas M., Lloreta J.,
RA   Carrato A., Tardon A., Serra C., Real F.X.;
RT   "PIK3CA mutations are an early genetic alteration associated with
RT   FGFR3 mutations in superficial papillary bladder tumors.";
RL   Cancer Res. 66:7401-7404(2006).
RX   PubMed=19105184; DOI=10.1002/pmic.200800121;
RA   Makridakis M., Gagos S., Petrolekas A., Roubelakis M.G., Bitsika V.,
RA   Stravodimos K., Pavlakis K., Anagnou N.P., Coleman J., Vlahou A.;
RT   "Chromosomal and proteome analysis of a new T24-based cell line model
RT   for aggressive bladder cancer.";
RL   Proteomics 9:287-298(2009).
RX   PubMed=19375735; DOI=10.1016/j.juro.2009.01.108;
RA   Chiong E., Dadbin A., Harris L.D., Sabichi A.L., Grossman H.B.;
RT   "The use of short tandem repeat profiling to characterize human
RT   bladder cancer cell lines.";
RL   J. Urol. 181:2737-2748(2009).
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
RX   PubMed=23401075; DOI=10.1002/path.4176;
RA   Guo Y., Chekaluk Y., Zhang J., Du J., Gray N.S., Wu C.-L.,
RA   Kwiatkowski D.J.;
RT   "TSC1 involvement in bladder cancer: diverse effects and therapeutic
RT   implications.";
RL   J. Pathol. 230:17-27(2013).
RX   PubMed=24018021; DOI=10.1016/j.eururo.2013.08.052;
RA   Allory Y., Beukers W., Sagrera A., Flandez M., Marques M., Marquez M.,
RA   van der Keur K.A., Dyrskjot L., Lurkin I., Vermeij M., Carrato A.,
RA   Lloreta J., Lorente J.A., Carrillo-de-Santa-Pau E., Masius R.G.,
RA   Kogevinas M., Steyerberg E.W., van Tilborg A.A.G., Abas C.,
RA   Orntoft T.F., Zuiverloon T.C.M., Malats N., Zwarthoff E.C., Real F.X.;
RT   "Telomerase reverse transcriptase promoter mutations in bladder
RT   cancer: high frequency across stages, detection in urine, and lack of
RT   association with outcome.";
RL   Eur. Urol. 65:360-366(2014).
RX   PubMed=24035680; DOI=10.1016/j.eururo.2013.08.057;
RA   Hurst C.D., Platt F.M., Knowles M.A.;
RT   "Comprehensive mutation analysis of the TERT promoter in bladder
RT   cancer and detection of mutations in voided urine.";
RL   Eur. Urol. 65:367-369(2014).
RX   PubMed=24367658; DOI=10.1371/journal.pone.0084411;
RA   Ross R.L., Burns J.E., Taylor C.F., Mellor P., Anderson D.H.,
RA   Knowles M.A.;
RT   "Identification of mutations in distinct regions of p85 alpha in
RT   urothelial cancer.";
RL   PLoS ONE 8:E84411-E84411(2013).
RX   PubMed=24376083; DOI=10.1002/pmic.201300452;
RA   Jeppesen D.K., Nawrocki A., Jensen S.G., Thorsen K., Whitehead B.,
RA   Howard K.A., Dyrskjot L., Orntoft T.F., Larsen M.R., Ostenfeld M.S.;
RT   "Quantitative proteomics of fractionated membrane and lumen exosome
RT   proteins from isogenic metastatic and nonmetastatic bladder cancer
RT   cells reveal differential expression of EMT factors.";
RL   Proteomics 14:699-712(2014).
RX   PubMed=24459064; DOI=10.1007/s13277-013-1604-3;
RA   Pinto-Leite R., Carreira I., Melo J., Ferreira S.I., Ribeiro I.,
RA   Ferreira J., Filipe M., Bernardo C., Arantes-Rodrigues R.,
RA   Oliveira P., Santos L.;
RT   "Genomic characterization of three urinary bladder cancer cell lines:
RT   understanding genomic types of urinary bladder cancer.";
RL   Tumor Biol. 35:4599-4617(2014).
RX   PubMed=25997541; DOI=10.1186/s12864-015-1450-3;
RA   Earl J., Rico D., Carrillo-de-Santa-Pau E., Rodriguez-Santiago B.,
RA   Mendez-Pertuz M., Auer H., Gomez G., Grossman H.B., Pisano D.G.,
RA   Schulz W.A., Perez-Jurado L.A., Carrato A., Theodorescu D.,
RA   Chanock S.J., Valencia A., Real F.X.;
RT   "The UBC-40 Urothelial Bladder Cancer cell line index: a genomic
RT   resource for functional studies.";
RL   BMC Genomics 16:403.1-403.16(2015).
RX   PubMed=26055179; DOI=10.1016/j.tranon.2015.04.002;
RA   Vallo S., Michaelis M., Rothweiler F., Bartsch G., Gust K.M.,
RA   Limbart D.M., Rodel F., Wezel F., Haferkamp A., Cinatl J. Jr.;
RT   "Drug-resistant urothelial cancer cell lines display diverse
RT   sensitivity profiles to potential second-line therapeutics.";
RL   Transl. Oncol. 8:210-216(2015).
RX   PubMed=26972028; DOI=10.1016/j.jprot.2016.03.008;
RA   Masuishi Y., Kimura Y., Arakawa N., Hirano H.;
RT   "Identification of glycosylphosphatidylinositol-anchored proteins and
RT   omega-sites using TiO2-based affinity purification followed by
RT   hydrogen fluoride treatment.";
RL   J. Proteomics 139:77-83(2016).
RX   PubMed=27141528; DOI=10.1016/j.dib.2016.04.001;
RA   Masuishi Y., Kimura Y., Arakawa N., Hirano H.;
RT   "Data for identification of GPI-anchored peptides and omega-sites in
RT   cancer cell lines.";
RL   Data Brief 7:1302-1305(2016).
RX   PubMed=27270441; DOI=10.1038/onc.2016.172;
RA   Nickerson M.L., Witte N., Im K.M., Turan S., Owens C., Misner K.,
RA   Tsang S.X., Cai Z., Wu S., Dean M., Costello J.C., Theodorescu D.;
RT   "Molecular analysis of urothelial cancer cell lines for modeling tumor
RT   biology and drug response.";
RL   Oncogene 36:35-46(2017).
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
RX   PubMed=29732388; DOI=10.3233/BLC-180167;
RA   Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.;
RT   "Systematic review: characteristics and preclinical uses of bladder
RT   cancer cell lines.";
RL   Bladder Cancer 4:169-183(2018).
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E., Schweppe D.K.,
RA   Jedrychowski M., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).